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Objective: To systematically review evidence on genetic variants
inﬂuencing outcomes during warfarin therapy and provide practice
recommendations addressing the key questions: (1) Should genetic
testing be performed in patients with an indication for warfarin
therapy to improve achievement of stable anticoagulation and reduce
adverse effects? (2) Are there subgroups of patients who may beneﬁt
more from genetic testing compared with others? (3) How should
patients with an indication for warfarin therapy be managed based on
their genetic test results?
Methods: A systematic literature search was performed for
VKORC1 and CYP2C9 and their association with warfarin therapy.
Evidence was critically appraised, and clinical practice recommen-
dations were developed based on expert group consensus.
Results: Testing of VKORC1 (21639G.A), CYP2C9*2, and
CYP2C9*3 should be considered for all patients, including pediatric
patients, within the ﬁrst 2 weeks of therapy or after a bleeding event.
Testing for CYP2C9*5, *6, *8, or *11 and CYP4F2 (V433M) is
currently not recommended. Testing should also be considered for
all patients who are at increased risk of bleeding complications, who
consistently show out-of-range international normalized ratios, or
suffer adverse events while receiving warfarin. Genotyping results
should be interpreted using a pharmacogenetic dosing algorithm to
estimate the required dose.
Signiﬁcance: This review provides the latest update on genetic
markers for warfarin therapy, clinical practice recommendations as
a basis for informed decision making regarding the use of genotype-
guided dosing in patients with an indication for warfarin therapy, and
identiﬁes knowledge gaps to guide future research.
Key Words: warfarin, VKORC1, CYP2C9, clinical practice recom-
mendations, genetic testing
(Ther Drug Monit 2015;37:428–436)
INTRODUCTION
Warfarin
Warfarin is an oral anticoagulant used for the pre-
vention and treatment of thromboembolic events. The list of
indications for warfarin is extensive but includes atrial
ﬁbrillation, prosthetic heart valves, history of vascular
thrombosis, or after orthopedic surgery.1 Warfarin is still
widely considered the mainstay of anticoagulation therapy,
with approximately 2 million people started on warfarin annu-
ally in the United States.2
Warfarin is administered as a racemic mixture of R- and
S-enantiomers. S-warfarin is approximately 2–5 times more
potent than R-warfarin and is almost exclusively metabolized
by the cytochrome P450 2C9 (CYP2C9) enzyme in the
liver.1,3 Warfarin acts as an anticoagulant by inhibiting the
vitamin K epoxide reductase complex (VKORC1) and block-
ing regeneration of reduced vitamin K that is essential for the
activation of speciﬁc coagulation factors.1,4,5
Warfarin Dosing and Adverse Drug Reactions
Clinical management and therapeutic monitoring of
warfarin is achieved using the International Normalized Ratio
(INR). A population-based initial warfarin dose is prescribed
(eg, 5–10 mg/d), and subsequent dose changes are made to
achieve an INR in the therapeutic range typically between 2
and 3. Use of warfarin is limited by a large interpatient var-
iability in dose requirement, making both safe and effective
therapeutic dosing of warfarin difﬁcult to achieve. An INR
below 2 increases the risk of thromboembolism, whereas an
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INR above 4 greatly increases the risk of bleeding.6,7 Achiev-
ing the target INR can take weeks and puts patients at
increased risk of adverse drug reactions (ADRs) during the
initiation period.8 Bleeding is the most common ADR asso-
ciated with warfarin therapy, with the incidence of major
bleeding ranging from 0% to 16% and the incidence of fatal
bleeding reported as 0%–2.9%.9 Warfarin is the second most
common drug implicated in emergency department visits and
the most often cited cause of drug-related mortality.10,11
Genetic Variants
CYP2C9
CYP2C9 is a member of the cytochrome P450
superfamily of enzymes, which are responsible for the
metabolism and elimination of many common prescription
drugs. Approximately 5%–30% of the population carry var-
iants of the CYP2C9 gene, which result in an enzyme with
reduced or 0 activity.12 Patients carrying such variants have
an impaired ability to metabolize warfarin, resulting in
increased levels of the active S-warfarin metabolite and
a decreased dose requirement to obtain therapeutic INR.13
In Europeans, the 2 most common variants that confer
reduced enzyme activity are CYP2C9*2 and CYP2C9*3
(see Table 1, Supplemental Digital Content 1, http://links.
lww.com/TDM/A107).14 The frequencies of both variants are
lower in African and Asian populations (Table 1). Additional
CYP2C9 gene variants, such as CYP2C9*5, *6, *8, and *11,
also result in reduced enzyme activity and are more common
in African Americans.15–18
VKORC1
A speciﬁc variant in VKORC1 (21639G.A) alters the
rate at which the gene is transcribed and results in lower protein
expression. Patients who carry the A variant require lower
warfarin doses, whereas patients who carry 2 copies of the
VKORC1-1639 G allele are more resistant to the anticoagula-
tion effects of warfarin (see Table 2, Supplemental Digital
Content 1, http://links.lww.com/TDM/A107).19 Therefore, this
single-nucleotide polymorphism can be used to differentiate
patients with high (AA), normal (AG), and low (GG) warfarin
sensitivity. As with the CYP2C9 variants, the frequency of the
21639G.A variant differs among ethnic groups, occurring
most frequently in Asians (82%–96%)20 (Table 1). This ﬁnding
helps explain historical interethnic differences in warfarin dose
requirements, as Asians on average require a lower warfarin
dose compared with Caucasians and Africans.19 Several rare
point mutations in VKORC1 have also been associated with
warfarin resistance.21–24 These variants occur in the coding
region of the gene and lead to changes in the VKORC1 protein
sequence, potentially affecting the warfarin site of action.22
However, the function of VKORC1 in extreme warfarin resis-
tance is still poorly understood.
CYP4F2
CYP4F2 is a vitamin K oxidase that catalyzes the
metabolism of vitamin K to hydroxyvitamin K1 and functions
as a counterpart to VKORC1 to prevent accumulation of
vitamin K. A functional polymorphism in the CYP4F2 gene
(V433M) encodes a protein with decreased activity, resulting
in increased levels of vitamin K.25 An increase in the amount of
vitamin K available for the activation of vitamin K-dependent
clotting factors results in a higher warfarin dose requirement in
patients carrying this polymorphism.25
Genetic and Clinical Factors
Interpatient variability in warfarin dose can also be
partially be explained by patient-speciﬁc factors, such as age,
body surface area, and illness.26 Patients who consume large
amount of dietary vitamin K also require signiﬁcantly higher
warfarin doses to prevent subtherapeutic dosing.27 Addition-
ally, medications that impact warfarin pharmacokinetics or
pharmacodynamics can also dramatically alter dose require-
ment.28 For example, drug inhibition of the warfarin metab-
olizing enzyme CYP2C9 can alter warfarin pharmacokinetics,
resulting in a decreased warfarin dose requirement.28 In pa-
tients receiving multiple concomitant medications, the asso-
ciation between genetic variants and warfarin dose is reduced
because of the additional nongenetic variability in dose re-
quirements introduced by the effect of these drugs on warfarin
metabolism.29,30 The relative importance of genetics for pre-
dicting warfarin dose can therefore be modulated by environ-
mental factors, which should be taken into consideration
when estimating warfarin dose requirements.
Scope and Purpose
The purpose of this review is to provide clinical practice
recommendations on both the prospective utility of pharma-
cogenetic testing and on genotype-speciﬁc treatment options to
enable medical professionals to make more informed decisions
about optimal warfarin therapy. In particular, this document
addresses the following key questions:
1. In treatment of patients with an indication for warfarin,
does the use of genetic testing before initiation of warfarin,
when compared with no testing, improve achievement of
stable anticoagulation and reduce adverse effects?
2. Are there subpopulations of patients where testing will be
less beneﬁcial/more beneﬁcial compared with others?
3. How should patients with an indication for warfarin ther-
apy be managed based on their genotyping results?
By addressing these key questions, we hope to clearly
deﬁne how genetic testing should be incorporated into warfarin
therapy to gain maximum beneﬁts and limit patient harm. The
recommendations provided should be interpreted in the context
of the unique clinical circumstances for each patient.
TABLE 1. Allele Frequencies Across Ethnic Groups for CYP2C9
and VKORC120
Allele
Ethnic Group
European, % African, % Asian, %
CYP2C9*2 8–15 0–4 0
CYP2C9*3 6–8 0–2 2–5
CYP2C9*5 0 1–3 0
CYP2C9*6 0 0–2 0
CYP2C9*8 0 2–8 0
CYP2C9*11 0 1–5 0
VKORC1 (21639G.A) 31–48 3–15 82–96
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METHODS
A standard guideline development process was fol-
lowed in accordance with the quality criteria suggested by
the Appraisal of Guidelines Research and Evaluation
Enterprise (AGREE), an international endeavor aimed at
improving the quality of practice guidelines.31,32 This pro-
cess involved a systematic literature search followed by
critical appraisal of the retrieved evidence (Table 2). Clin-
ical practice recommendations were developed during
a workshop meeting of guideline development group mem-
bers. Recommendations were assigned 1 of 3 levels based
on the strength of scientiﬁc evidence on which the recom-
mendations were formed, as well as the balance between
beneﬁts and risks for genotype-guided therapy (Table 3).
Draft guideline documents were submitted to a tiered
review process, which included internal review by the
guideline development group members, followed by exter-
nal review both by content experts and by members of the
intended target audience. Additional details on the litera-
ture search strategy, evidence review and appraisal, and
recommendation development are provided in the Supple-
mental Digital Content 1 (see Data, http://links.lww.com/
TDM/A107).
CLINICAL PRACTICE RECOMMENDATIONS
Should Pharmacogenetic Testing Be
Performed in Warfarin-Naive Patients Before
Initiation of Warfarin Therapy?
Testing of all warfarin-naive patients for VKORC1
(21639G.A), CYP2C9*2, and CYP2C9*3 should be con-
sidered before initiation of therapy and within the ﬁrst 2 weeks
of therapy (level B—Table 3). Genetic testing for CYP2C9*5,
*6, *8, or *11 and CYP4F2 V433M is currently not recom-
mended (C).
Considerations
Carriers of VKORC1 (21639G.A), CYP2C9*2, and
CYP2C9*3 require a signiﬁcantly lower warfarin dose com-
pared with wild-type carriers. They also require less time to
reach a therapeutic INR, are more likely to become overanti-
coagulated (INR $4), and are at greater risk of experiencing
an adverse event. There is inconsistent but encouraging evi-
dence that pharmacogenetic-guided dosing increases time
within the therapeutic range and reduces hospitalization rates
of patients on warfarin therapy.
Testing should be performed before initiating therapy.
If this is not feasible, we recommend that testing be
considered if test results can be obtained within the ﬁrst 2
weeks of therapy, as genetic information can still be useful for
estimating the maintenance dose. After 2 weeks, the beneﬁts
derived from genetic testing are reduced.
At this time, we do not recommend testing for
CYP2C9*5, *6, *8, or *11 for any patients. Although there
is strong evidence of an association between these variants
and required dose in African Americans, it remains unclear
how inﬂuential these single-nucleotide polymorphisms are
when other CYP2C9 and VKORC1 genotypes are considered
and how best to determine an appropriate dose when this
information is available as they were not included in most
studies evaluating genotype-guided dosing algorithms. How-
ever, if CYP2C9*5 or *6 genotype is already known for
a speciﬁc patient, they can be incorporated into the dosing
algorithm at www.WarfarinDosing.org. We make the same
recommendation for testing of CYP4F2 V433M, which can
also be entered into the web-based dosing algorithm.
Are There Subpopulations of Patients Where
Testing Will Be Less Beneficial/More
Beneficial Compared With Others?
Testing should be considered for all patients who are at
increased risk of bleeding complications, who consistently
show out-of-range INRs, or suffer adverse events while
receiving warfarin (B). We also recommended that testing
be considered for all pediatric patients (B). Testing is not
recommended in patients who have reached a stable INR (A).
Considerations
For the majority of patients, we do not recommend
genetic testing once a stable INR has been reached. However,
genetic testing should be performed if patients consistently
TABLE 2. Grading Scheme Used for Critical Appraisal of
Evidence
Grade Results Description
++++ Consistent, generalizable Strong general conclusions can
be drawn that are unlikely to
change based on further
research
+++ Consistent, but limited
quantity, quality, or
generalizability
Evidence allows general
conclusions, but with
reduced conﬁdence; further
research is likely to have an
important impact on
conﬁdence in conclusions
++ Inconsistent or insufﬁcient
quantity/quality,
encouraging
No general conclusions can be
drawn or conclusions are
likely to change based on
further research, but current
evidence is encouraging
+ Inconsistent or insufﬁcient
quantity/quality,
discouraging
No conclusions can be drawn
or conclusions are likely to
change based on future
studies, and current evidence
is discouraging
TABLE 3. Grading Scheme Used for Clinical Practice
Recommendations
Level Strength Evidence Basis
A Strong Based on strong scientiﬁc evidence,
beneﬁts clearly outweigh risks
B Moderate Based on reduced conﬁdence
scientiﬁc evidence and expert
opinion, beneﬁts likely to outweigh
risks
C Optional Based mainly on expert opinion, for
use with evidence development in
a research context
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show out-of-range INR values or ﬂuctuations in INR values
for more than 3–4 weeks that are not accounted for by other
variables (eg, elderly age, elevated baseline INR, hypoalbu-
minemic patients, impaired nutrition, heart failure, concomi-
tant medications that increase sensitivity to warfarin, dietary
measures). Genetic testing should also be considered for pa-
tients who are at increased risk of bleeding complications.
Speciﬁc risk factors for bleeding include older age, history
of gastrointestinal (GI) tract bleeding, hypertension, cerebro-
vascular disease, serious heart disease, anemia, malignancy,
trauma, renal insufﬁciency, recent percutaneous coronary
intervention, new onset atrial ﬁbrillation, and patients who
are receiving triple therapy (clopidogrel, aspirin, and warfa-
rin).33–35 We also recommend testing patients who suffer
bleeding events while on warfarin therapy, as this may help
to determine whether the underlying cause of bleeding was
likely due to diet, concomitant medications or other clinical
factors, or as a result of genetic variants. In this instance,
discerning the reason for the bleeding episode could help
prevent future bleeding events and allow for safer manage-
ment of these patients overall.
Emerging evidence suggests a strong association between
genetic variants and required warfarin dose and warfarin-related
outcomes in children. Although the impact of genotype-guided
dosing on clinical outcomes has not yet been studied in children,
we recommend that testing also be considered for all pediatric
patients within the ﬁrst 2 weeks of warfarin therapy because of
consistent genetic associations (level B).
How Should Patients With an Indication for
Warfarin Therapy Be Managed Based on
Their Genotyping Results?
Genotyping results should be interpreted using a phar-
macogenetic dosing algorithm to estimate the required dose
(A). Several pharmacogenetic dosing algorithms are available
for use, including algorithms accessible online at www.
warfarindosing.org and as an iWarfarin application.
After testing for CYP2C9*2, CYP2C9*3, and VKORC1
(21639G.A), pharmacogenetic dosing algorithms that
incorporate both clinical variables and genetic information
should be used to predict a stable warfarin dose. These
include the International Warfarin Pharmacogenetics Consor-
tium (IWPC) model,36 which is available as the iPhone/iPad/
iPod application iWarfarin,37 and the updated Gage et al
model found at www.WarfarinDosing.org. These algorithms
have previously been shown to posses the greatest predictive
ability and are easily accessible for clinicians.38–40
We recommend using the FDA-approved dosing table
provided on the warfarin label insert (see Table 3, Supple-
mental Digital Content 1, http://links.lww.com/TDM/A107)
when physicians are unable to access pharmacogenetic dosing
algorithms. These dose recommendations are derived from
a large database containing both clinical and genetic informa-
tion; however, the table does not incorporate relevant patient-
speciﬁc clinical factors. Given that clinical factors also
signiﬁcantly affect warfarin dose, dosing algorithms that con-
sider both genetic and clinical information should be
preferred.41
There are several pediatric-derived dosing algorithms
that have also been published.42–46 We recommend using the
model developed by Biss et al, as the accuracy of this model
has been validated using retrospective data in replication co-
horts.44,47,48 To date, none of the pediatric dosing algorithms
have been evaluated in prospective cohorts and are not avail-
able as a ready-to-use computer/phone application or Web
site. Alternatively, the IWPC model has also been shown to
be predictive of maintenance dose in children, although it is
less accurate compared with pediatric-derived pharmacoge-
netic dosing models.43,44
Currently, validated genetic tests are not routinely
available in some hospitals or outpatient laboratories. For
those that offer these tests, the turnaround time for test results
that meet the requirements set forth by Clinical Laboratory
Standards Institute is approximately 5–10 days (eg, Mayo and
Arup laboratories). The technology is available where the ana-
lytical turnaround time is about 24 hours, thus improvement in
turnaround time is expected. For now, healthcare providers
should consult their local laboratories for test availability and
turnaround time to optimize patient management. A list of
testing laboratories is provided in the Supplemental Digital
Content 1 (see Table 4, http://links.lww.com/TDM/A107).
We do not recommend delaying therapy for test results in cases
where anticoagulation is required immediately. Rather, de-
pending on when test results are available, they can be incor-
porated into a dose-reﬁnement algorithm after the initiation of
therapy (eg, WRAPID, www.warfarindosing.org).
Of importance, pharmacogenetic-guided dosing should
not replace regular INR monitoring. Rather, test results should
be used to help physicians estimate an appropriate warfarin
dose, while still using regular INR monitoring to ensure that
stable anticoagulation is achieved. In all situations, informed
decision making and informed consent are required by patients
after counseling on the use, beneﬁts and risks, and implications
of these tests by the healthcare provider.
EVIDENCE SUMMARY
A detailed description of supporting evidence is pro-
vided in the Supplemental Digital Content 1 (see Data,
http://links.lww.com/TDM/A107). Here, we provide a brief
summary and appraisal of the evidence for certain outcomes
investigated.
Warfarin Dose Is Correlated With CYP2C9 and
VKORC1 Genotypes
There is strong evidence (++++evidence, Table 2) that
the required warfarin dose is associated with VKORC1-1639,
CYP2C9*2, and CYP2C9*3 variants (see Table 6, Supple-
mental Digital Content 1, http://links.lww.com/TDM/A107).
This is based on a large number of studies showing consistent
results. Importantly, these studies were comprised a diverse
patient population, including African Americans, Caucasians,
Japanese, Han Chinese, Hispanics, Indians, and several other
ethnicities. The majority of studies (39 of 47) found that
VKORC1 is the most important genetic factor inﬂuencing var-
iability in warfarin dosing (Table 4). When comparing ethnic
populations, this variant accounts for the largest amount of
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dose variability in East and West Asians and the least
amount in African Americans (Table 4). Up to 47% of the
variation in warfarin dosing can be explained by the
VKORC1 genotype (Table 4).49
CYP2C9 is the second strongest genetic factor associated
with warfarin dose,50 accounting for approximately 2%–27%
of the variability (Table 4).29,42 The *2 and *3 variants are most
frequent in Caucasians and contribute to the larger impact on
dose variability in this population compared with other popu-
lations (Table 4).20 Accordingly, the amount of variability ex-
plained by CYP2C9*2 and *3 is less in African American and
Asians, likely due to the lower frequency of these alleles.
Association Between Warfarin Dose and
CYP4F2 Genotype
The overall evidence grading for an association between
CYP4F2 genotype and required warfarin dose is moderate
(++evidence). This grading is based on inconsistent results
across studies, particularly regarding the amount of variability
explained by CYP4F2 (ranges from 1% to 11%).51,52 More-
over, the clinical utility of including CYP4F2 in dosing models
that already include VKORC1 and CYP2C9 remains unclear.
Further studies are required to determine the clinical beneﬁt of
incorporating this variant into a dosing algorithm.
Stable Warfarin Dose Is More Accurately
Predicted by Genotype-Guided Dosing
Compared With Standard Dosing or Clinical
Algorithms
There is strong evidence (++++, Table 2) that pharma-
cogenetic dosing algorithms more accurately predict the stable
warfarin dose when compared with standard empirical dosing
or clinical dosing algorithms. This is based on consistent ﬁnd-
ings across all studies included in the evidence summary.
The pharmacogenetic dosing algorithms most com-
monly tested were those developed by Gage et al,53 Sconce
et al,54 and the IWPC.36 When Sagreiya et al38 compared
these 3 algorithms, as well as an additional 4 algorithms, with
the IWPC clinical algorithm, they found that the models of
IWPC pharmacogenetics and Gage et al possessed the great-
est predictive ability and performed very similarly (IWPC:
R2 = 0.50, Gage: R2 = 0.49, Clinical: R2 = 22). Furthermore,
all pharmacogenetic models outperformed the IWPC clinical
model in terms of R2 and mean absolute error values when
predicting the required dose.
A novel pharmacogenetics-guided initiation and main-
tenance dosing regimen was also investigated in a prospective
cohort study (WRAPID; see Table 5, Supplemental Digital
Content 1, http://links.lww.com/TDM/A107).39 As INRs
became available, they were entered into the algorithm, along
with clinical variables and genetics, to determine an appro-
priate maintenance dose. When the algorithm was applied to
all study participants, the proportion of variance explained by
the maintenance dose regression model was 42%, whereas the
variance explained after INR-guided dose adjustments was
70%. Therefore, prediction of maintenance dose may be further
improved by incorporating initiation INRs into a genetics-
based dosing algorithm.
Time to Therapeutic/Stable INR
Time to therapeutic or stable INR is frequently used as
a clinical end point because once a stable INR is reached,
patients are less likely to show ﬂuctuations in subsequent INR
measurements and the risk of bleeding is signiﬁcantly
reduced.55 When evaluating this outcome, both observational
and intervention studies were considered. The overall evidence
grading for association between CYP2C9 and VKORC1 geno-
types and time to ﬁrst therapeutic INR is fairly strong (+++
evidence). This is based on consistent results from a large num-
ber of studies. However, the association between genetic var-
iants and time required to reach stable INR, deﬁned as
consecutive INRs in the therapeutic range, is less consistent
and needs to be evaluated further. Based on results from inter-
vention studies, the evidence for genotype-guided dosing to
reduce the amount of time required to reach therapeutic/stable
INR is inconsistent (++evidence). Six of the 11 studies that
prospectively compared standard dosing practices with
genotype-guided dosing found that the time to reach therapeutic
INR was signiﬁcantly shorter in the genotype-guided group. All
studies evaluated were randomized controlled trials (RCTs),
with the exception of 1 study in which every patient was dosed
using a pharmacogenetics-based dosing model. Because of
a possibility of “over management” of patients, the results
may not reﬂect real-world outcomes. Based on inconsistent
ﬁndings and differences in study quality and the comparison
groups evaluated, no general conclusions can be drawn.
Time Within the Therapeutic INR Range
The strength of evidence for an association between
genotype and time spent in the therapeutic INR range for the
duration of warfarin therapy is low (+evidence). This is
mainly due to a limited quantity of studies (n = 3) and a lack
of signiﬁcant ﬁndings. However, the evidence for genotype-
guided dosing to increase the amount of time spent in the
therapeutic range is insufﬁcient but encouraging (++evi-
dence). All intervention studies reported that patients who
received pharmacogenetic-guided dosing spent more time in
the therapeutic range compared with the control group;
TABLE 4. Variability in Warfarin Dose Explained by VKORC1 and CYP2C9 Genotypes in Different Ethnic Populations
Genotype Caucasian, % East Asian, % West Asian, % Hispanic, % African/African American, %
VKORC1 21639G.A 13.8–4749,65 19.8–35.566,67 20.3–34.168,69 11.3–30.370,71 4–915,72
CYP2C9*2 or *3 2–2729,42 3.4–11.273,74 8.1–19.069,75 7.1–870,71 ,5.615,16
CYP2C9*5,*6,*8,*11 NA NA NA NA ,5–616,76
NA, not available.
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however, there were inconsistencies in the magnitude of
effect and not all ﬁndings were statistically signiﬁcant. Based
on studies that reported a signiﬁcant ﬁnding, genotype-guided
dosing increased the amount of time within the therapeutic
range by 7%–21% compared with using empirical dosing or
clinical dosing algorithms. Nevertheless, no general conclu-
sions can be drawn at this time.
Time to INR ‡4 or Incidence/Frequency of
INR ‡4
The incidence/frequency of INR measurements $4 is
often used as a surrogate marker for the risk of bleeding
complications during warfarin therapy.56 The evidence grad-
ing for an association between CYP2C9 and VKORC1 geno-
type and incidence of INR $4 is fairly strong (+++evidence).
This is due to a large number of studies reporting consistent
results. However, based on the available evidence, it is
unclear whether genotype is associated with incidence of
INR $4 in African Americans and whether being heterozy-
gous for VKORC1 also increases the risk of INR $4. Only 1
observational study investigated time to INR $4 and found
that carriers of CYP2C9/VKORC1 variants required signiﬁ-
cantly less time to reach an INR .4 compared with noncar-
riers, representing a risk for overanticoagulation.57 More
evidence is needed before this association can be comprehen-
sively assessed. In contrast, the evidence grading for
genotype-guided dosing to decrease the incidence or time to
INR $4 is low (+evidence). Four of 5 studies reported no
difference in incidence/time to INR $4 between genotype-
guided dosing and control patients. One study that used phar-
macogenetic dosing in all patients did not ﬁnd a signiﬁcant
difference in time to INR .4 between genotype groups, sug-
gesting an elimination of genotype-related differences that
have been reported in observational studies.39
Incidence of Adverse Events
There is fairly strong evidence that CYP2C9 and
VKORC1 genotypes are associated with warfarin-induced
adverse events (+++evidence). Speciﬁcally, 14 of 17 studies
reported a signiﬁcant association between genotypes and inci-
dence of bleeding events. The association is strongest with
CYP2C9 variant genotypes, whereas there is less evidence of
an association with the VKORC1 genotype. Further research
is required to determine the role of VKORC1 in warfarin-
induced bleeding events. In prospective studies that investi-
gated warfarin-induced adverse events, there is insufﬁcient
evidence (++evidence) that genotype-guided dosing can
decrease the number of adverse events. With the exception
of 1 study, it was consistently shown that there is a trend
toward less adverse events in the genotype-guided dosing
group, suggesting that the rarity of warfarin-induced adverse
events may contribute to nonsigniﬁcant ﬁndings rather than
a lack of association. However, 1 study used historical con-
trols, whereas another study combined adverse events with
other clinical outcomes for analyses, potentially biasing the
results in favor of genotype-guided dosing. Overall, the lack
of consistent signiﬁcant ﬁndings weakens the evidence for
this outcome.
FUTURE DIRECTIONS
Pharmacogenetic dosing algorithms have been shown
to predict warfarin doses to a certain degree of conﬁdence.
However, their ability to improve clinical outcomes (eg,
decrease the number of bleeding events) remains to be
conﬁrmed with a greater level of conﬁdence. In 2013, 2
large RCTs investigating the clinical beneﬁt of genotype-
based warfarin dosing were published but provided different
conclusions. The EU-PACT trial58 (n = 455) reported that
genotype-based dosing was associated with a higher per-
centage of time in the therapeutic range compared with stan-
dard dosing (67.4% versus 60.3%, P , 0.001), whereas the
COAG trial59 (n = 1015) found that there was no difference
between genotype-guided dosing and dose determined using
a clinical algorithm when investigating the same primary
outcome (45.2% versus 45.4%; P = 0.91). Some key differ-
ences between the 2 studies were length of follow-up time
(12 weeks for EU-PACT and 4 weeks for COAG), determi-
nation of dose in the nongenotype group (ﬁxed dose in EU-
PACT and clinical dosing algorithm in COAG), patient
ancestry (2% non-Caucasian in EU-PACT and 33% non-
Caucasian in COAG), and the availability of genetic test
results (EU-PACT genotype results were available in
approximately 2 hours, COAG genotype results were not
available before the ﬁrst dose for 55% of patients). These
differences in study design may have largely impacted the
primary outcomes.
These studies also raise questions about the ability of
RCTs to reﬂect real-world clinical settings and whether
studies conducted in very controlled settings and specialized
centers are appropriate for determining the clinical utility of
pharmacogenetic testing in warfarin therapy. It has pre-
viously been noted that in the case of warfarin RCTs,
patients in the control group may be “over managed” com-
pared with standard clinical care, diluting the anticipated
effect of genotype-based dosing on clinical outcomes. An
alternative approach could be a prospective nonrandomized
study where genetic testing is incorporated into clinical care
and compared with standard dosing practices in a more real-
istic setting to better determine the utility of genetic test-
ing.60–62 Two ongoing RCTs [WARFARIN Study
(NCT01305148) and GIFT (NCT01006733)] are using inci-
dence of adverse events, including bleeding and thrombo-
embolism, as the primary study outcomes. This is in contrast
to COAG and EU-PACT, which used time in therapeutic
range as a primary outcome. Using a more clinically relevant
outcome such as adverse events may also help to more accu-
rately represent the true clinical utility of genotype-guided
dosing, as well as give a better understanding of the relative
importance of VKORC1 and CYP2C9 variants in the context
of warfarin ADRs. The design of future prospective inter-
ventional studies should also consider newly discovered fac-
tors inﬂuencing warfarin dose, including novel genetic
variants in African Americans and differences in response
between patient groups [eg, venous thromboembolism
(VTE) versus atrial ﬁbrillation],63 as well as differences
between clinical settings to better evaluate the clinical utility
of genotype-guided warfarin dosing.
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Table 5 summarizes research gaps that require further
consideration. Speciﬁcally, future research should aim to
improve the accuracy of pharmacogenetic dosing algorithms
in non-European patients. This could include incorporating
additional CYP2C9 and VKORC1 variants into dosing models
to account for interethnic differences in genotype frequency
and dose requirements or genome-wide association studies in
homogeneous patient cohorts to discover novel genetic
markers that are ethnic speciﬁc. Optimization of dosing algo-
rithms in patients with a target INR range outside of 2–3 is
also needed.
Genotype-based initiation dose algorithms, such as
those developed by Gong et al39 and Avery et al,40 also
require further investigation. The use of initiation doses
may be especially important in VTE patients, as these patients
have shown to be more resistant to warfarin’s therapeutic
effect when compared with atrial ﬁbrillation patients.13 How-
ever, there is concern over using initiation doses, as some
patients may become overanticoagulated and be at higher risk
of bleeding. More information is required regarding the clin-
ical utility of genetics-based initiation dose algorithms and
whether these algorithms are more beneﬁcial for speciﬁc
patient populations that have historically required higher war-
farin doses (eg, VTE patients).
Currently, approximately 50% of the dose variation can
be explained by clinical and genetic factors combined.
Potential sources of missing information include additional
genetic variation, epigenetic factors, additional drug–drug in-
teractions, and patient behaviors, including diet, exercise, and
compliance.64 Future pharmacogenetic studies that are able to
control for environmental factors may reveal additional
genetic variants implicated in warfarin dosing.
The investigation of rare variants in CYP2C9 and
VKORC1 may also improve the prediction of extreme pheno-
types (extremely high warfarin sensitivity or warfarin resis-
tance). Rost et al21 identiﬁed 4 VKOR variants that confer
reduced catalytic activity and are associated with “warfarin
resistance.” Further studies are required to elucidate the
mechanisms behind extreme phenotypes and the predictive
value of these rare variants.
New oral anticoagulants (NOACs) are now available as
a possible alternative to warfarin and offer some advantages,
including rapid onset and lack of need for monitoring.
However, the paucity of information regarding safety and
effectiveness of NOACs warrants further research and long-
term evaluation of these compounds. It is expected that as
new compounds emerge, warfarin will remain an important
and frequently used drug given its proven efﬁcacy, low cost,
and years of physician experience compared with NOACs.
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